FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566883225> ?p ?o ?g. }

• W2566883225 abstract "Abstract Varicella-zoster virus (VZV) infection remains a common complication after hematopoietic stem cell transplantation (HSCT). The introduction of long-term prophylaxis with low-dose acyclovir against VZV reactivation has been investigated, because VZV-related complications including post-herpetic neuralgia and secondary infection significantly affect the patient’s quality of life. We started long-term oral acyclovir at 200 mg/day in July 2001. Acyclovir was continued until the end of immunosuppressive therapy and at least one year after transplantation. To evaluate the efficacy of this long-term prophylaxis with ultra low-dose acyclovir against VZV reactivation, we analyzed the records of 242 Japanese adult patients who underwent allogeneic HSCT for the first time from June, 1995 to November, 2006 at University of Tokyo Hospital. Sixty-six patients developed VZV reactivation at a median of 248 days after HSCT, with a cumulative incidence of 34.7%. There was no VZV-related death. Only one breakthrough reactivation occurred during long-term acyclovir, responding well to the therapeutic dose of valacyclovir. The use of long-term acyclovir was the only independent determinant that significantly decreased the overall incidence of VZV reactivation (20.4% vs 50.5%, P&lt;0.0001). As for VZV-related complications, only post-herpetic neuralgia was seen in three patients with long-term prophylaxis, whereas serious complications including CNS involvement, motor neuropathy and ophthalmic complications were involved in 14 without long-term prophylaxis. Eleven of 16 patients with long-term prophylaxis were treated as outpatients, whereas 39 of 50 patients without long-term prophylaxis required hospitalization (hospitalization 31% vs 78%, P=0.0015). Fifteen of the 57 patients who discontinued long-term acyclovir developed VZV reactivation at a median of 147 days after the discontinuation of acyclovir, with a cumulative incidence of 32.1%. VZV reactivation following discontinuation predominantly occurred in patients who were receiving immunosuppressive therapy at the cessation of acyclovir (44% vs 20%, P=0.12). These findings suggest that long-term prophylaxis of ultra-low-dose acyclovir resulted in a successful prevention of severe VZV-related symptoms and death, with a significantly decreased overall incidence of VZV reactivation. With this prophylaxis, visceral dissemination and serious complications other than post-herpetic neuralgia were completely eliminated, and thereby need for hospitalization was significantly reduced. To continue acyclovir for patients with profound immunosuppression might be important to further decrease the overall incidence of VZV reactivation. Figure Figure" @default.
• W2566883225 created "2017-01-06" @default.
• W2566883225 creator A5009975594 @default.
• W2566883225 creator A5022371062 @default.
• W2566883225 creator A5027118202 @default.
• W2566883225 creator A5036559617 @default.
• W2566883225 creator A5047768108 @default.
• W2566883225 creator A5050365213 @default.
• W2566883225 creator A5052158230 @default.
• W2566883225 creator A5055406060 @default.
• W2566883225 creator A5060858053 @default.
• W2566883225 creator A5067604014 @default.
• W2566883225 creator A5067804516 @default.
• W2566883225 creator A5070366230 @default.
• W2566883225 creator A5084289729 @default.
• W2566883225 creator A5085077147 @default.
• W2566883225 creator A5085709435 @default.
• W2566883225 date "2007-11-16" @default.
• W2566883225 modified "2023-09-30" @default.
• W2566883225 title "Long-Term Ultra-Low-Dose Acyclovir Against Varicella-Zoster Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation." @default.
• W2566883225 cites W152700816 @default.
• W2566883225 cites W1973617793 @default.
• W2566883225 cites W2000452027 @default.
• W2566883225 cites W2000686577 @default.
• W2566883225 cites W2012544930 @default.
• W2566883225 cites W2025148744 @default.
• W2566883225 cites W2039773104 @default.
• W2566883225 cites W2040226771 @default.
• W2566883225 cites W2041954668 @default.
• W2566883225 cites W2072409794 @default.
• W2566883225 cites W2076206356 @default.
• W2566883225 cites W2081187342 @default.
• W2566883225 cites W2119845492 @default.
• W2566883225 cites W2124497768 @default.
• W2566883225 doi "https://doi.org/10.1182/blood.v110.11.1967.1967" @default.
• W2566883225 hasPublicationYear "2007" @default.
• W2566883225 type Work @default.
• W2566883225 sameAs 2566883225 @default.
• W2566883225 citedByCount "0" @default.
• W2566883225 crossrefType "journal-article" @default.
• W2566883225 hasAuthorship W2566883225A5009975594 @default.
• W2566883225 hasAuthorship W2566883225A5022371062 @default.
• W2566883225 hasAuthorship W2566883225A5027118202 @default.
• W2566883225 hasAuthorship W2566883225A5036559617 @default.
• W2566883225 hasAuthorship W2566883225A5047768108 @default.
• W2566883225 hasAuthorship W2566883225A5050365213 @default.
• W2566883225 hasAuthorship W2566883225A5052158230 @default.
• W2566883225 hasAuthorship W2566883225A5055406060 @default.
• W2566883225 hasAuthorship W2566883225A5060858053 @default.
• W2566883225 hasAuthorship W2566883225A5067604014 @default.
• W2566883225 hasAuthorship W2566883225A5067804516 @default.
• W2566883225 hasAuthorship W2566883225A5070366230 @default.
• W2566883225 hasAuthorship W2566883225A5084289729 @default.
• W2566883225 hasAuthorship W2566883225A5085077147 @default.
• W2566883225 hasAuthorship W2566883225A5085709435 @default.
• W2566883225 hasConcept C120665830 @default.
• W2566883225 hasConcept C121332964 @default.
• W2566883225 hasConcept C126322002 @default.
• W2566883225 hasConcept C141071460 @default.
• W2566883225 hasConcept C187212893 @default.
• W2566883225 hasConcept C203014093 @default.
• W2566883225 hasConcept C2522874641 @default.
• W2566883225 hasConcept C2776159415 @default.
• W2566883225 hasConcept C2776409557 @default.
• W2566883225 hasConcept C2777408962 @default.
• W2566883225 hasConcept C2779450786 @default.
• W2566883225 hasConcept C2780727368 @default.
• W2566883225 hasConcept C2911091166 @default.
• W2566883225 hasConcept C61511704 @default.
• W2566883225 hasConcept C71924100 @default.
• W2566883225 hasConcept C81182388 @default.
• W2566883225 hasConcept C88879693 @default.
• W2566883225 hasConcept C90924648 @default.
• W2566883225 hasConceptScore W2566883225C120665830 @default.
• W2566883225 hasConceptScore W2566883225C121332964 @default.
• W2566883225 hasConceptScore W2566883225C126322002 @default.
• W2566883225 hasConceptScore W2566883225C141071460 @default.
• W2566883225 hasConceptScore W2566883225C187212893 @default.
• W2566883225 hasConceptScore W2566883225C203014093 @default.
• W2566883225 hasConceptScore W2566883225C2522874641 @default.
• W2566883225 hasConceptScore W2566883225C2776159415 @default.
• W2566883225 hasConceptScore W2566883225C2776409557 @default.
• W2566883225 hasConceptScore W2566883225C2777408962 @default.
• W2566883225 hasConceptScore W2566883225C2779450786 @default.
• W2566883225 hasConceptScore W2566883225C2780727368 @default.
• W2566883225 hasConceptScore W2566883225C2911091166 @default.
• W2566883225 hasConceptScore W2566883225C61511704 @default.
• W2566883225 hasConceptScore W2566883225C71924100 @default.
• W2566883225 hasConceptScore W2566883225C81182388 @default.
• W2566883225 hasConceptScore W2566883225C88879693 @default.
• W2566883225 hasConceptScore W2566883225C90924648 @default.
• W2566883225 hasLocation W25668832251 @default.
• W2566883225 hasOpenAccess W2566883225 @default.
• W2566883225 hasPrimaryLocation W25668832251 @default.
• W2566883225 hasRelatedWork W1977314954 @default.
• W2566883225 hasRelatedWork W2017277443 @default.
• W2566883225 hasRelatedWork W2065387512 @default.
• W2566883225 hasRelatedWork W2069721889 @default.
• W2566883225 hasRelatedWork W2360260519 @default.
• W2566883225 hasRelatedWork W2474039552 @default.

• next